Raymond James & Associates Tekla Life Sciences Investors Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Tekla Life Sciences Investors stock. As of the latest transaction made, Raymond James & Associates holds 44,147 shares of HQL stock, worth $595,984. This represents 0.0% of its overall portfolio holdings.

Number of Shares

44,147

Previous 39,335 12.23%

Holding current value

$595,984

Previous $557,000 19.39%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$14.26 - $15.78 $68,619 - $75,933	4,812 Added 12.23%	44,147 $665,000
Q2 2024 Jul 19, 2024	BUY	$12.79 - $14.27 $122,528 - $136,706	9,580 Added 32.2%	39,335 $557,000
Q1 2024 Apr 22, 2024	BUY	$13.38 - $14.33 $45,933 - $49,194	3,433 Added 13.04%	29,755 $405,000
Q4 2023 Jan 16, 2024	SELL	$11.35 - $13.6 $16,446 - $19,706	-1,449 Reduced 5.22%	26,322 $354,000
Q3 2023 Oct 24, 2023	SELL	$12.38 - $13.69 $1.69 Million - $1.87 Million	-136,694 Reduced 83.11%	27,771 $346,000
Q2 2023 Jul 25, 2023	SELL	$13.13 - $14.17 $1.91 Million - $2.07 Million	-145,739 Reduced 46.98%	164,465 $2.23 Million
Q1 2023 Apr 14, 2023	BUY	$13.37 - $14.94 $731,619 - $817,531	54,721 Added 21.42%	310,204 $4.32 Million
Q4 2022 Feb 08, 2023	BUY	$13.55 - $15.23 $1.16 Million - $1.31 Million	85,818 Added 50.58%	255,483 $3.63 Million
Q3 2022 Oct 25, 2022	BUY	$13.39 - $16.31 $2.11 Million - $2.57 Million	157,719 Added 1320.27%	169,665 $2.32 Million
Q2 2022 Aug 12, 2022	SELL	$13.11 - $17.02 $160,741 - $208,682	-12,261 Reduced 50.65%	11,946 $170,000
Q1 2022 May 11, 2022	SELL	$15.35 - $19.29 $877,544 - $1.1 Million	-57,169 Reduced 70.25%	24,207 $400,000
Q4 2021 Feb 08, 2022	BUY	$18.5 - $21.59 $319,902 - $373,334	17,292 Added 26.98%	81,376 $1.57 Million
Q3 2021 Nov 02, 2021	SELL	$20.27 - $22.67 $587 - $657	-29 Reduced 0.05%	64,084 $1.33 Million
Q2 2021 Aug 11, 2021	BUY	$19.14 - $21.44 $50,204 - $56,237	2,623 Added 4.27%	64,113 $1.38 Million
Q1 2021 May 14, 2021	BUY	$19.31 - $22.07 $587,255 - $671,192	30,412 Added 97.86%	61,490 $1.21 Million
Q4 2020 Feb 12, 2021	SELL	$16.8 - $20.21 $355,992 - $428,249	-21,190 Reduced 40.54%	31,078 $614,000
Q3 2020 Nov 04, 2020	SELL	$16.71 - $19.06 $25,967 - $29,619	-1,554 Reduced 2.89%	52,268 $919,000
Q2 2020 Jul 28, 2020	SELL	$14.22 - $18.38 $184,860 - $238,940	-13,000 Reduced 19.45%	53,822 $967,000
Q1 2020 Apr 21, 2020	SELL	$12.22 - $17.99 $259,980 - $382,737	-21,275 Reduced 24.15%	66,822 $1 Million
Q4 2019 Feb 12, 2020	SELL	$14.63 - $17.84 $1.15 Million - $1.41 Million	-78,806 Reduced 47.22%	88,097 $1.54 Million
Q3 2019 Nov 07, 2019	SELL	$15.09 - $17.09 $749,580 - $848,928	-49,674 Reduced 22.94%	166,903 $2.52 Million
Q2 2019 Aug 06, 2019	SELL	$15.54 - $17.47 $956,098 - $1.07 Million	-61,525 Reduced 22.12%	216,577 $3.65 Million
Q1 2019 May 06, 2019	SELL	$15.5 - $17.9 $282,177 - $325,869	-18,205 Reduced 6.14%	278,102 $4.76 Million
Q4 2018 Feb 11, 2019	SELL	$13.99 - $20.35 $219,195 - $318,843	-15,668 Reduced 5.02%	296,307 $4.48 Million
Q3 2018 Nov 14, 2018	BUY	$18.89 - $20.49 $162,095 - $175,824	8,581 Added 2.83%	311,975 $6.37 Million
Q2 2018 Aug 14, 2018	BUY	$18.13 - $19.4 $531,136 - $568,342	29,296 Added 10.69%	303,394 $5.7 Million
Q1 2018 May 14, 2018	BUY	$18.92 - $21.52 $512,353 - $582,761	27,080 Added 10.96%	274,098 $5.27 Million
Q4 2017 Feb 14, 2018	BUY	$18.31 - $22.24 $2.58 Million - $3.14 Million	140,994 Added 132.98%	247,018 $4.85 Million
Q3 2017 Nov 13, 2017	SELL	$20.12 - $21.88 $66,154 - $71,941	-3,288 Reduced 3.01%	106,024 $2.28 Million
Q2 2017 Aug 14, 2017	BUY	N/A	109,312	109,312 $2.28 Million

Others Institutions Holding HQL

# of Institutions

Shares Held

9.31M

Call Options Held

Put Options Held

View Full List

About TEKLA LIFE SCIENCES INVESTORS

Ticker HQL
Exchange NYSE
Sector Financial Services
Industry Asset Management
Description
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical...

More about HQL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Tekla Life Sciences Investors Transaction History